(Reuters) – StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85%. The magnitude of the treatment’s effect did not justify continuing the study given the financial resources available, StemCells said on Tuesday. The Newark, California-based biotech said […]
StemCells says spinal injury therapy shows promise
(Reuters) — StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. The biotech company said interim results from the mid-stage study showed 4 of 6 patients experienced an improvement on 2 different scales. […]
Pluristem launches Phase I clinical trial to treat tendonitis with stem cells
Pluristem (NSDQ:PSTI) announced a new Phase I clinical trial to treat chronic tendonitis with the company’s PLX-PAD stem cell therapy.
Cell therapy has traditionally been used in cancer and cardiac treatments, but Pluristem is now applying the technology to sports-related injuries, where it has seen an increased interest among athletes and orthopedic surgeons.
Geron’s exit from stem cell business means opportunity for InVivo, others
